-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Dual Targeted Regimens for the Front-line Treatment of CLL

Program: Education Program
Session: How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023?
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Research
Saturday, December 9, 2023, 2:00 PM-3:15 PM

Chaitra S Ujjani, MD

Fred Hutchinson Cancer Center, Seattle, WA

Disclosures: Ujjani: Lilly: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Pharmacyclics: Consultancy, Honoraria, Research Funding; Genentech: Consultancy, Honoraria; Astrazeneca: Consultancy, Honoraria, Research Funding; Epizyme: Consultancy; Kite, a Gilead Company: Consultancy, Other: Travel expenses , Research Funding; PCYC: Research Funding; Beigene: Consultancy, Honoraria; Abbvie: Consultancy, Honoraria, Research Funding; Atara: Consultancy.

OffLabel Disclosure: The combination of BCL2 and BTK inhibitors is off label

See more of: How Do We Extend Survival for Patients with Chronic Lymphocytic Leukemia (CLL) in 2023?
See more of: Education Program
Previous Presentation | Next Presentation >>